Home
Research and Applications
Advisors
Management
Contact Us
Zoltan Kiss Consulting (ZKC), a start-up family-owned biotechnological company, has discovered the potential of a non-toxic human protein (ZKCPr1) to treat various health conditions in obese mice with the expectation that the research data will be applicable to humans as well.
ZKCPr1, used in both recombinant and highly purified forms, is the product of human placenta and research data strongly indicates its important role in fetus development explaining why it has no detectable side effects.
The half-life time of ZKCPr1 in the circulation of mice and humans is about 4 and 10 days, respectively. This protein shows significant resistance to proteases which explains its relative stability particularly in the human circulation. Such metabolic stability allows its administration via the oral route particularly when suitable coating is also applied.
The various research programs of ZKC utilizing ZKCPr1 along with potential applications are summarized in the following section. In addition, application of a method for weight maintenance using heterocyclic compounds is also outlined.